Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 28 April 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Chronic cough and gastroesophageal reflux disease

Researchers from Rochester, New York, find that 4 to 6 weeks of a proton-pump inhibitor successfully diagnoses and treats most patients with GERD-related cough.

News image

fiogf49gjkf04

In this study, researchers evaluated proton-pump inhibitor therapy, with or without a prokinetic agent, in the diagnosis and treatment of gastroesophageal reflux disease (GERD)-related cough.

The team performed a review of their experience of 214 patients with a cough of 3 weeks, referred over a 3 and a half year period.

The cough was eliminated or markedly improved in 86% of patients after 4 weeks.
Chest

Their findings are published in the March issue of Chest.

Overall, the team identified 183 patients with chronic cough, these were included in the study. However, 31 patients were disqualified because of abnormal chest radiographic findings, inadequate follow-up, or cough being not the primary complaint.

Of the 183 patients, 56 were identified as having GERD-related cough.

The team prescribed these patients a once-daily dose of a proton-pump inhibitor.

In addition, the team added a prokinetic agent if esophageal dysfunction was suspected, or response was inadequate.

Patients who did not respond underwent 24-hour esophageal pH monitoring.

The research team found that GERD was the single cause of cough in 43% of patients. A further 52% had GERD plus another cause, and 5% patients had GERD with more than 2 causes.

The team also determined that 43% of patients had a cough only, while 57% had other symptoms of GERD.

Overall, proton-pump therapy was successful in 79% of patients.

The team found that 24 patients responded to proton-pump inhibitor therapy, and 18 patients responded when metoclopramide or cisapride was added. The remaining 2 patients responded to a histamine type-2 blocker or cisapride alone.

The cough was eliminated or markedly improved in 86% of patients after 4 weeks, and by 8 weeks in the remaining 6 patients.

The team found that 6 of the nonresponders had aspiration diagnosed by bronchoscopy.

Additionally, 4 patients had fundoplication recommended, and 2 patients responded to alternative interventions.

Drs Robert Poe and Michael Kallay concluded, "4 to 6 weeks of a proton-pump inhibitor alone or in combination with a prokinetic agent successfully diagnoses and treats 4 of 5 patients with GERD-related cough".

"24-hour esophageal pH monitoring will confirm the diagnosis in the others."

"These patients may be candidates for fundoplication."

"Nonresponders often aspirate as an additional aggravating factor."

Chest 2003; 123: 679-84
14 March 2003

Go to top of page Email this page Email this page to a colleague

 28 April 2017 
Anastomotic leak in colorectal cancer
 28 April 2017 
Yoga for ulcerative colitis
 28 April 2017 
Risk of pain after liver transarterial chemoembolization
 27 April 2017 
Precision oncology in liver cancer
 27 April 2017 
Celiac disease in adolescents with susceptibility genotypes
 27 April 2017 
Esophageal endocscopic submucosal dissection
 26 April 2017 
Time to colonoscopy and colorectal cancer
 26 April 2017 
National gastric cancer screening program
 26 April 2017 
Iron formulations for anemia in IBD
 25 April 2017 
Asymptomatic carriers and C. diff
 25 April 2017 
Telemedicine tool for IBD
 25 April 2017 
Biologics for mucosal healing in IBD
 24 April 2017 
Poor oral health and IBD
 24 April 2017 
Bacterial infections in cirrhosis 
 24 April 2017 
Functional dyspepsia and duodenal eosinophilia
 21 April 2017 
Treatment of abdominal pain in IBS 
 21 April 2017 
Improving adenoma detection rate
 21 April 2017 
Infection after living donor liver transplantation
 20 April 2017 
Diagnosis of small colorectal polyps
 20 April 2017 
Diagnosis of GERD
 20 April 2017 
Prediction of HCV vertical transmission
 19 April 2017 
Iron replacement therapy in IBD
 19 April 2017 
Heat stroke leading to acute liver failure
 19 April 2017 
Pregnancy and anti-TNF agents in IBD
 14 April 2017 
Water exchange and adenoma detection rate
 14 April 2017 
Survival in IBD associated colorectal cancer
 14 April 2017 
Tacrolimus for liver transplantation
 14 April 2017 
GastroHep.com Easter break
 13 April 2017 
Hepatic manifestations of IBD
 13 April 2017 
Multidisciplinary approach to pancreas cancer
 13 April 2017 
Predicting post-operative Crohn's recurrence
 12 April 2017 
Liver disease in patients for liver transplant
 12 April 2017 
Management of common bile duct stones
 12 April 2017 
Nucleotide analogues for Hep B and cancer risk
 11 April 2017 
Interferon-free regimens for HCV-related Child C cirrhosis
 11 April 2017 
Biodgradable stents and benign intestinal strictures
 11 April 2017 
Weight loss after nutrition training
 10 April 2017 
Polymorphisms associated with liver injury from statins
 10 April 2017 
Genetic risk factors in IBD infections
 10 April 2017 
Regimens for HCV-related Child C cirrhosis
 07 April 2017 
Transition readiness scores in adolescents with IBD
 07 April 2017 
IBD disability index
 07 April 2017 
Hepatocellular carcinoma risk in different etiologies of cirrhosis
 06 April 2017 
Antidepressants in IBD
 06 April 2017 
Meal fat content and reflux
 06 April 2017 
Hep C treatment transformation with direct antiviral agents
 05 April 2017 
Threatening life experiences in ulcerative colitis
 05 April 2017 
Prednisolone and mortality in alcoholic hepatitis 
 05 April 2017 
5-aminosalicylates and colorectal cancer in IBD
 04 April 2017 
Celiac disease in the elderly
 04 April 2017 
IBS after infectious enteritis
 04 April 2017 
Diarrhea after allogeneic stem cell transplantation
 03 April 2017 
Minorities at increased gastric cancer risk
 03 April 2017 
Incidence and risk factors of IBD
 03 April 2017 
Western diet and diverticulitis
 31 March 2017 
GI safety of direct oral anticoagulants
 31 March 2017 
Screening for celiac disease
 31 March 2017 
Low-FODMAP diet in patients with functional GI disorders
 30 March 2017 
Low-grade esophageal dysplasia and cancer risk
 30 March 2017 
Poor oral health and IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us